MedWatch

Analyst: Improved market conditions will support Lundbeck's key products in Q1

On Wednesday, when the pharmaceutical firm hands in its first quarterly report for 2022, onlookers should pay attention to four key products, says a Sydbank analyst.

Photo: Lundbeck / PR

As the pandemic has eased up, and restrictions have been lifted, pharmaceutical firm Lundbeck’s market conditions have improved. This should be evident in the firm’s first quarterly report, which is slated to release on Wednesday, an analyst says.

This is because more people have been able to begin treatments in hospitals again.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs